Yuko Mishima

2.3k citations

113 papers · 1.5k indexed · h-index 24

Impact in

Pathology and Forensic Medicine top 2%
- Lymphoma Diagnosis and Treatment
- Cancer Mechanisms and Therapy
Genetics top 5%
- Chronic Lymphocytic Leukemia Research

Papers in

Pathology and Forensic Medicine 52
- Lymphoma Diagnosis and Treatment 49
Hematology 24
- Multiple Myeloma Research and Treatments 13

Co-authors: Kiyohiko Hatake Yasuhito Terui Masahiro Yokoyama Kengo Takeuchi Shunji Takahashi Daisuke Ennishi Yuji Mishima Mitsune Tanimoto
Journals: Blood (19 papers)International Journal of Hematology (8 papers)Cancer Science (5 papers)Annals of Oncology (4 papers)Scientific Reports (3 papers)
Partner nations: Japan United States United Kingdom

In The Last Decade

Yuko Mishima

104 papers receiving 1.5k citations

Peers

Countries citing papers authored by Yuko Mishima

Since Specialization

Citations

This map shows the geographic impact of Yuko Mishima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuko Mishima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuko Mishima more than expected).

Fields of papers citing papers by Yuko Mishima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuko Mishima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuko Mishima. The network helps show where Yuko Mishima may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Yuko Mishima, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yuko Mishima Line = papers co-authored together Yuko Mishima links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	P33-7 Two patients with DLBCL who developed aortitis following pegfilgrastim administration during chemoimmunotherapy Annals of Oncology ·和夫安達, Hiroaki Asai, Kabita Sarma, I. Arrue, Theodor Stribel, А.С. Войтенко, Lorenzo Todesco, Yuko Ishihara, Yuko Mishima, Dai Maruyama	2023	0
2	Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma Japanese Journal of Clinical Oncology ·Wataru Munakata, Koji Izutsu, Yuko Mishima, Hirokazu Nagai, Yuko Ishihara, Junji Suzumiya, Yuzuru Kanakura, Toshihiro Nanki, Yang Weixiu, Axel Delgado Amador, G. Hungerbuhler, Kenichi Ishizawa	2023	2
3	Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B‐cell lymphoma Cancer Science ·Koji Izutsu, 山内克典, Junichiro Yuda, Hirokazu Nagai, Yuko Mishima, Youko Suehiro, Kazuhito Yamamoto, Tomoaki Fujisaki, Kenji Ishitsuka, Kenichi Ishizawa, Takayuki Ikezoe, Momoko Nishikori, Daigo Akahane, Jiro Fujita, Ronglin Xia, K. Oles, Saber Bouaouina, Helga Sofia West, Elena Favaro, Noriko Fukuhara	2023	12
4	Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11 International Journal of Hematology ·Shinsuke Iida, Kazutaka Sunami, Yuko Mishima, 文信洙, Kateřina Šujanová, 楊慶楠, M Schirosa, Jutta Nungesser, Qiong Liu, Brandon E. Kremer, Ira Gupta	2023	3
5	In vitro effects of Gla-domainless factor Xa analog on procoagulant and fibrinolytic pathways in apixaban-treated plasma and whole blood Thrombosis Research ·Polina A. Kipp, Luiz Gustavo Teixeira Pinto, Amir L. Butt, Yuko Mishima, Pratama Yuda Wibawa Siswanto, Sujith S. Dermal, Kenichi A. Tanaka	2023	0
6	Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study International Journal of Hematology ·Hideki Goto, Koji Izutsu, Daisuke Ennishi, Yuko Mishima, Shinichi Makita, Koji Kato, 小塚久志, Satoshi Hirano, Dirceu Pereira de Lima, Takanori Teshima, Hirokazu Nagai, Kenichi Ishizawa	2022	9
7	Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCL Clinical Lymphoma Myeloma & Leukemia ·Carmen Yamileth Armijos Cabrera, Noriko Nishimura, Mohammad Saeid Rezaee-Zavareh, Hirofumi Yamauchi, Naoko Tsuyama, Kengo Takeuchi, Yuko Mishima, Masahiro Yokoyama, Toshie Ogasawara, Naoki Mori, Tetsuya Ogawa, Hiroshi Sakura, Yasuhito Terui	2020	5
8	MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era Leukemia Research ·Noriko Nishimura, Kengo Takeuchi, Reimi Asaka, Ziji Lv, Mohammad Saeid Rezaee-Zavareh, Rajarshi Gayen, Yuko Mishima, Masahiro Yokoyama, Yasuhito Terui	2020	7
9	Chitin promotes antigen-specific Th2 cell-mediated murine asthma through induction of IL-33-mediated IL-1β production by DCs Scientific Reports ·Ken Arae, Hideaki Morita, Hirotoshi Unno, Kenichiro Motomura, Sumika Toyama, Naoko Okada, Tatsukuni Ohno, Masato Tamari, Keisuke Orimo, Yuko Mishima, Hajime Suto, Ko Okumura, Katsuko Sudo, Hiroshi Miyazawa, Haruhiko Taguchi, Hirohisa Saito, Kenji Matsumoto, Susumu Nakae	2018	23
10	Delayed recovery of serum immunoglobulin G is a poor prognostic marker in patients with follicular lymphoma treated with rituximab maintenance Annals of Hematology ·Rajarshi Gayen, Masahiro Yokoyama, Mohammad Saeid Rezaee-Zavareh, Hirofumi Yamauchi, Հրանտ Կոստանյան, Naoko Tsuyama, Yuko Mishima, Noriko Nishimura, Kengo Takeuchi, Yasuhito Terui, Kiyohiko Hatake	2017	2
11	Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma Molecular Cancer Therapeutics ·Diana Cirstea, Loredana Santo, Teru Hideshima, Homare Eda, Yuko Mishima, Neeharika Nemani, Anuj Mahindra, Andrew J. Yee, Güllü Görgün, Yiguo Hu, Hiroto Ohguchi, Rikio Suzuki, Francesca Cottini, Sylvie M. Guichard, Kenneth C. Anderson, Noopur Raje	2014	24
12	High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism International Immunology ·Yuji Mishima, Yasuhito Terui, Yuko Mishima, Iranis Romero Paiffer, Satoshi Matsusaka, Yangyang Wu, Kiyotsugu Kojima, Kiyohiko Hatake	2012	28
13	Cancer of unknown primary site: a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in Japan. PubMed ·Hisakazu Nishimori, Shunji Takahashi, Katsuyuki Kiura, Daisuke Ennishi, Takayuki Kobayashi, Koji Sano, Eiji Shinozaki, Masahiro Yokoyama, Yuko Mishima, Yasuhito Terui, Keisho Chìn, Nobuyuki Mizunuma, Yoshinori Ito, Seiichiro Nishimura, Kengo Takeuchi, Yuichi Ishikawa, Masahiko Oguchi, Mitsune Tanimoto, Kiyohiko Hatake	2010	5
14	Phase I study of inotuzumab ozogamicin (CMC‐544) in Japanese patients with follicular lymphoma pretreated with rituximab‐based therapy Cancer Science ·Michinori Ogura, Kensei Tobinai, Kiyohiko Hatake, Toshiki Uchida, Masanobu Kasai, Takashi Oyama, Tatsuya Suzuki, Yukio Kobayashi, Takashi Watanabe, Teruhisa Azuma, Masakazu Mori, Yasuhito Terui, Masahiro Yokoyama, Yuko Mishima, Shunji Takahashi, Chiho Ono, Junko Ohata	2010	46
15	Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors Cancer Science ·Yuko Mishima, (unknown), Yasuhito Terui, Yuji Mishima, Margaret Conery, Iranis Romero Paiffer, Toshihiro Takizawa, Shinya Kimura, Keiya Ozawa, Kiyohiko Hatake	2008	53
16	CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy Annals of Oncology ·Daisuke Ennishi, Kengo Takeuchi, Masaru Yokoyama, Hiroaki Asai, Yuko Mishima, Y. Terui, Shunji Takahashi, Hirotake Komatsu, Kazuma Ikeda, Motoko Yamaguchi, Ritsuro Suzuki, Mitsune Tanimoto, Kiyohiko Hatake	2008	67
17	What is the clinical significance of stromal angiogenesis in Barrett's esophagus? Journal of Gastroenterology and Hepatology ·Nobuyuki Moriyama, Yuji Amano, Yuko Mishima, Koichi Okita, Yoshiko Takahashi, Takafumi Yuki, Norihisa Ishimura, Shunji Ishihara, Yoshikazu Kinoshita	2008	8
18	A Japanese case of eosinophilic esophagitis Journal of Gastroenterology ·Koichiro Furuta, Kyoichi Adachi, Larissa Batista Da Silva, Yuko Mishima, Hiroshi Imaoka, Alexis Llamas-Jiménez, Nehidy García Riaño, Tatsuya Miyake, Yasunori Kadowaki, Kenji Furuta, Hideaki Kazumori, Shuichi Sato, Shunji Ishihara, Yuji Amano, Masaaki Honda, Yoshikazu Kinoshita	2006	54
19	Blockade of bulky lymphoma‐associated CD55 expression by RNA interference overcomes resistance to complement‐dependent cytotoxicity with rituximab Cancer Science ·Yasuhito Terui, Takuma Sakurai, Yuko Mishima, Yuji Mishima, Natsuhiko Sugimura, H.A. Adamu, Kiyotsugu Kojima, Masahiro Yokoyama, Nobuyuki Mizunuma, Shunji Takahashi, Yoshinori Ito, Kiyohiko Hatake	2005	54
20	Histologic features of gastric cancer in relation to patterns of spread. PubMed ·Zenro Nihei, Ryuichi Hirayama, Masaki Sakamoto, Yuko Mishima	1989	7

About Yuko Mishima

Yuko Mishima is a scholar working on Pathology and Forensic Medicine, Hematology, Genetics, Oncology and Otorhinolaryngology, having authored 113 papers that have together received 1.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (49 papers), Chronic Lymphocytic Leukemia Research (20 papers), Multiple Myeloma Research and Treatments (13 papers), CNS Lymphoma Diagnosis and Treatment (10 papers), CAR-T cell therapy research (10 papers), Viral-associated cancers and disorders (9 papers), Gastric Cancer Management and Outcomes (8 papers) and Immune Cell Function and Interaction (6 papers). The work is most often cited by research in Pathology and Forensic Medicine (512 citations), Genetics (266 citations), Oncology (507 citations), Hematology (197 citations) and Gastroenterology (87 citations). Yuko Mishima has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Kiyohiko Hatake, Yasuhito Terui, Masahiro Yokoyama, Kengo Takeuchi, Shunji Takahashi, Daisuke Ennishi, Yuji Mishima, Mitsune Tanimoto, Yuji Amano and Shunji Ishihara. Their work appears in journals such as Blood, International Journal of Hematology, Cancer Science, Annals of Oncology and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact